부산대학교 도서관

Heart failure (HF) is a complex diagnosis, consisting of numerous syndromes with a common presentation (typically with signs and symptoms of congestion and/or low cardiac output), but with variable prognosis. Given the challenging nature that HF poses to clinicians, measurement of circulating biomarkers has been increasingly used to diagnose HF more accurately, estimate its severity, and evaluate treatment adequacy. Central to the use of biomarkers in HF patients is the understanding that biomarkers are a supplement to clinical judgement. However, biomarkers such as natriuretic peptides have revolutionized how the diagnosis of HF is regarded. Newer biomarkers such as cardiac troponins, soluble ST2, genomic markers (such as microRNA), and multi-biomarker panels developed through proteomics may provide even greater future value to better understand the complex diagnosis and management of HF.